Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

• Qian Jiang,
• Zongru Li,
• Yazhen Qin,
• Weiming Li,
• Na Xu,
• Bingcheng Liu,
• Yanli Zhang,
• Li Meng,
• Huanling Zhu,
• Xin Du,
• Suning Chen,
• Yang Liang,
• Yu Hu,
• Xiaoli Liu,
• Yongping Song,
• Lichuang Men,
• Zi Chen,
• Qian Niu,
• Hengbang Wang,
• Ming Lu,
• Dajun Yang,
• Yifan Zhai,
• Xiaojun Huang

Affiliations

Qian Jiang

National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology

Zongru Li

National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology

Yazhen Qin

National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology

Weiming Li

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Na Xu

Department of Hematology, Nanfang Hospital, Southern Medical University

Bingcheng Liu

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College

Yanli Zhang

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital

Li Meng

Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology

Huanling Zhu

Department of Hematology, West China Hospital of Sichuan University

Xin Du

Division of Hematology, Shenzhen Second People’s Hospital, The First Affiliated Hospital of Shenzhen University

Suning Chen

National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology, Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University

Yang Liang

State Key Laboratory of Oncology in South China, Department of Hematologic Oncology, Collaborative Innovation Center for Cancer Medicine, Sun Yat-Sen University Cancer Center

Yu Hu

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Xiaoli Liu

Department of Hematology, Nanfang Hospital, Southern Medical University

Yongping Song

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital

Lichuang Men

Guangzhou Healthquest Pharma Co. Ltd.

Zi Chen

Guangzhou Healthquest Pharma Co. Ltd.

Qian Niu

Guangzhou Healthquest Pharma Co. Ltd.

Hengbang Wang

Guangzhou Healthquest Pharma Co. Ltd.

Ming Lu

Ascentage Pharma Group Inc

Dajun Yang

Ascentage Pharma (Suzhou) Co., Ltd

Yifan Zhai

Guangzhou Healthquest Pharma Co. Ltd.

Xiaojun Huang

National Clinical Research Center for Hematologic Disease, Peking University People’s Hospital, Peking University Institute of Hematology